Clinical trials: Age Related Maculopathy
Neovascular Age-related Macular Degeneration
Efficacy And Safety Of Macugen In Patients With Neovascular AMD In Routine Clinical Practice.
Efficacy and safety of MACUGEN in patients suffering from neovascular age-related macular degeneration in routine clinical practice at least as good as demonstrated in randomized multicenter clinical trials.
- Trial name
- MACULA (NCT00858208)
- Testing
- pegaptanib sodium
- Where
- 8 sites in Greece
- Volunteers
- 86 people
- Sponsor
- Pfizer
Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)
This is a multi-center, randomized, double-masked, active-comparator-controlled, Phase 3 study in a broad participant population (treatment-naïve and treatment-experienced) with neovascular (wet) age-related macular degeneration…
- Trial name
- AQUARIUS (NCT07482176)
- Testing
- Ixo-vec, Aflibercept
- Where
- 79 sites in United States
- Volunteers
- 534 people
- Sponsor
- Adverum Biotechnologies, Inc.
Wet Age-related Macular Degeneration
A Prospective, Observational, Multicentre, 2 Year Study Evaluating the Use of Eylea (Aflibercept) for the Treatment of Neovascular (Wet) Age-related Macular Degeneration in UK NHS Opthalmology Clinics
To assess the use of aflibercept over a 2 year period in VEGF inhibitor naive and prior treated wet AMD patients managed in 'real wold' clinic settings.
- Trial name
- NCT02005133
- Where
- 17 sites in United Kingdom
- Volunteers
- 188 people
- Sponsor
- Novartis Pharmaceuticals
Age-Related Macular Degeneration, Dry Age-related Macular Degeneration
Microcurrent Stimulation Therapy for Nonexudative Age-related Macular Degeneration (i-SIGHT)
Evaluate the safety and efficacy of transpalpebral microcurrent stimulation (MCS) therapy for patients with nonexudative (dry) age-related macular degeneration (AMD).
- Conditions
- Age-Related Macular Degeneration, Dry Age-related Macular Degeneration, Nonexudative Age-related Macular Degeneration
- Trial name
- i-SIGHT (NCT05447650)
- Testing
- i-Lumen(TM) AMD
- Where
- 10 sites in United States
- Volunteers
- 95 people
- Sponsor
- i-Lumen Scientific, Inc.
Age-Related Macular Degeneration (AMD)
MacuMira Microcurrent Stimulation for Dark Adaptation in Dry Age-Related Macular Degeneration
Age-related macular degeneration (AMD) is an eye condition that affects the retina and can lead to progressive vision loss. This study will evaluate the effects of MacuMira microcurrent stimulation on dark adaptation in adults…
- Trial name
- NCT07917715
- Testing
- Transpalpebral microcurrent electrical stimulation
- Where
- 3 sites in Canada
- Volunteers
- 50 people
- Sponsor
- Clarity Eye Institute
Polypoidal Choroidal Vasculopathy (PCV), Neovascular Age Related Macular Degeneration (AMD)
A Prospective, Multicenter, Open-label, Randomized Clinical Trial to Evaluate the Efficacy, Durability, and Safety of Aflibercept 8mg in Different Treatment Regimens in Chinese Patients With Polypoidal Choroidal Vasculopathy (PCV)
The goal of this clinical trial is to investigate the efficacy, durability, and safety of aflibercept 8 mg in treating Polypoidal Choroidal Vasculopathy (PCV) in Chinese naive patients.
- Trial name
- NCT07365371
- Testing
- Aflibercept Intravitreous Injection
- Where
- 20 sites in China
- Volunteers
- 174 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Maculopathy, Age-Related
Study of the Combination of Anecortave Acetate and Triamcinolone Acetonide for the Treatment of Exudative Age-Related Macular Degeneration (AMD)
The purpose of this study is to evaluate the safety of combining juxtasclerally administered anecortave acetate 15 mg with triamcinolone acetate 4 mg administered intravitreally following photodynamic therapy with verteporfin for…
- Trial name
- NCT00211419
- Testing
- Anecortave Acetate 15 mg, Triamcinolone Acetate 4 mg, Photodynamic Therapy with Verteporfin
- Where
- United States
- Sponsor
- Manhattan Eye, Ear & Throat Hospital
Healthy Volunteers, Wet Age-related Macular Degeneration
A Safety Study of KHK4951 in Healthy Volunteers and Patients With Wet Age-Related Macular Degeneration
The purpose of this study is to evaluate safety and tolerability after administration of KHK4951 in healthy volunteers and patients with wet age-related macular degeneration.
- Trial name
- NCT04594681
- Testing
- KHK4951
- Where
- Japan
- Volunteers
- 116 people, healthy volunteers welcome
- Sponsor
- Kyowa Kirin Co., Ltd.
Neovascular Age Related Macular Degeneration
Retinal Effects After Combined Photodynamic Therapy (PDT) With Intravitreal Triamcinolone
Background: To identify characteristic morphological changes of the retina, their change over time and the association with visual function after combined photodynamic therapy (PDT) and intravitreal triamcinolone (IVTA).
- Trial name
- NCT00685100
- Testing
- PDT plus intravitreal triamcinolone
- Volunteers
- 40 people
- Sponsor
- Medical University of Vienna
Neovascular Age-Related Macular Degeneration
A Non-interventional Study to Assess the Influence of Automated Optical Coherence Tomography Image Enrichment With Segmentation Information on Disease Activity Assessment in Patients Treated With Licensed Anti- VEGF Injections
RAZORBILL was an observational, multicenter, multinational, open-label, study designed primarily to investigate the influence of automated OCT image enrichment with segmentation information on disease activity assessment in nAMD…
- Trial name
- RAZORBILL (NCT04662944)
- Testing
- brolucizumab, ranibizumab, aflibercept
- Where
- 17 sites in Canada, Germany and 3 more
- Volunteers
- 494 people
- Sponsor
- Novartis Pharmaceuticals
Age-related Macular Degeneration
Multicenter Real-life Observational Study Switched Aflibercept or Ranibizumab to Faricimab in Patients With AMD.
Age-related macular degeneration (AMD) is a degenerative retinal disease. The prognosis of the exudative form was transformed by the introduction of the anti-VEGF monoclonal antibody treatments ranibizumab [1] and aflibercept [2]…
- Trial name
- FAR-WEST (NCT06271330)
- Testing
- Faricimab
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Nantes University Hospital
Age-Related Macular Degeneration
Study of Dark Adaptation in Age-Related Macular Degeneration
Background: Age-related macular degeneration (AMD) is a leading cause of vision loss in individuals over 55 years of age. It can cause permanent loss of central vision, which is important for seeing fine details and long…
- Trial name
- NCT01352975
- Where
- United States
- Volunteers
- 217 people
- Sponsor
- National Eye Institute (NEI)
AMD
Anecortave Acetate Risk-Reduction Trial (AART)
The purpose of this study was to demonstrate that Anecortave Acetate for Depot Suspension (15 mg or 30 mg) is safe and effective in arresting the progression of non-exudative (dry) age-related macular degeneration in patients who…
- Trial name
- NCT00333216
- Testing
- Anecortave Acetate Sterile Suspension, 30 mg/mL, Anecortave Acetate Sterile Suspension, 60 mg/ML, Anecortave Acetate Vehicle
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Alcon Research
Age-Related Macular Degeneration
Direct Discrimination of Quantum States by the Human Eye
Age-related macular degeneration (AMD), is a debilitating eye disease that causes a loss of central vision. The prevalence of AMD increases exponentially with age and causes a significant impact through both medical expenses and…
- Trial name
- NCT05913063
- Testing
- Structured Light Imaging Microscopy
- Where
- Hong Kong
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Centre for Eye and Vision Research
Age-related Macular Degeneration
Evaluation of AGN-150998 in Exudative Age-related Macular Degeneration (AMD)
This study is conducted in 3 stages. Stage 1 is an open-label, dose-escalation assessment of the safety of AGN-150998 administered as a single intravitreal injection to patients with advanced exudative Age-related Macular…
- Trial name
- NCT01397409
- Testing
- AGN-150998, ranibizumab
- Where
- 8 sites in United States, Australia and 6 more
- Volunteers
- 271 people
- Sponsor
- Allergan
Neovascular Age-related Macular Degeneration
An Extension Study Assessing the Efficacy and Safety of Brolucizumab in a Treat-to-Control Regimen in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2303 (TALON) Study
The purpose of this extension study was to evaluate the efficacy and safety of brolucizumab used in a Treat-to-Control-regimen for treatment of patients with neovascular age-related macular degeneration who have completed the…
- Trial name
- TALON Ext (NCT04597632)
- Testing
- brolucizumab
- Where
- 60 sites in United States, Australia and 14 more
- Volunteers
- 248 people
- Sponsor
- Novartis Pharmaceuticals
Dry Age-Related Macular Degeneration, Geographic Atrophy
Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated With Age-Related Macular Degeneration
Background: Age-related macular degeneration is a common eye disease in people over 50. The "dry" form of the disease can worsen into geographic atrophy, causing blind spots.
- Trial name
- NCT04339764
- Testing
- iPSC-derived RPE/PLGA transplantation
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- National Eye Institute (NEI)
Macular Degeneration
EYLEA Age-Related Macular Degeneration (AMD) Post-marketing Surveillance in Japan
This study is a regulatory post-marketing surveillance in Japan, and it is a local prospective and observational study of patients who have received EYLEA for Age-Related Macular Degeneration (AMD).
- Trial name
- NCT01756248
- Testing
- Aflibercept(Eylea, VEGF Trap-Eye, BAY86-5321)
- Where
- Japan
- Volunteers
- 3,872 people
- Sponsor
- Bayer
Neovascular Age-related Macular Degeneration, Wet Age-related Macular Degeneration
Safety and Tolerability of RGX-314 (Investigational Product) Gene Therapy for Neovascular AMD Trial
Excessive vascular endothelial growth factor (VEGF) plays a key part in promoting neovascularization and edema in neovascular (wet) age-related macular degeneration (nAMD).
- Trial name
- NCT03066258
- Testing
- RGX-314
- Where
- 8 sites in United States
- Volunteers
- 42 people
- Sponsor
- REGENXBIO Inc.
Recalcitrant Wet Age-related Macular Degeneration
Ranibizumab for Recalcitrant Wet Age-related Macular Degeneration in Eyes Previously Switched From Bevacizumab and/or Ranibizumab to Aflibercept.
The purpose of the study is to determine the effectiveness of Ranibizumab 0.5 mg or 1.0 mg in subjects who were previously treated with Bevacizumab and subsequently switched to Aflibercept.
- Trial name
- RESCUE (NCT01972763)
- Testing
- Ranibizumab
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Northern California Retina Vitreous Associates
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.